Company Filing History:
Years Active: 2007
Title: Innovations of Peter Hof in Diabetes Treatment
Introduction
Peter Hof is a notable inventor based in Martinsried, Germany. He has made significant contributions to the field of medical science, particularly in the treatment of diabetes-associated wounds. His innovative work has led to the development of a patent that addresses critical health issues.
Latest Patents
Peter Hof holds a patent for the "Use of α 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an ACT polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances." This invention focuses on the use of alpha 1-antichymotrypsin (ACT) polypeptides and their encoding nucleic acids for diagnosing, treating, and preventing poorly healing wounds associated with diabetes and arterial conditions.
Career Highlights
Throughout his career, Peter Hof has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Switch Biotech AG and Bayer Innovation GmbH. His experience in these organizations has contributed to his expertise in the field of medical innovations.
Collaborations
Peter Hof has collaborated with esteemed colleagues, including Jörn-Peter Halle and Andreas Goppelt. These partnerships have further enhanced his research and development efforts in the medical field.
Conclusion
Peter Hof's contributions to the treatment of diabetes-associated wounds through his innovative patent demonstrate his commitment to advancing medical science. His work continues to impact the healthcare industry positively.